May. 7 at 7:08 PM
$NAMS Interim analysis seems like a win/win. Either we get a positive result in Q1, or the trial continues for longer which will provide even more opportunity for curve separation, as we see in every LLT trial ever.
The main thing to watch out for during investor day is the event rate for year 1-2. We can then compare the decay in event rate to the decay rate seen in other trials (evolocumab, bempedoic acid, alirocumab, anacetrapib, evacetrapib) to get an idea if there is any drug effect.
